Syn X Pharma, Inc.

Artemis Proteomics, Ltd.

Nanogen, Inc.

Tammy Vrees

George Jackowski

John G Marshall

Jason Yantha

Brad Thatcher

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer.

Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons

Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of a biopolymer.

Biopolymer marker indicative of disease state having a molecular weight of 1525 Daltons

Method and kit for diagnosing myocardial infarction

Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer.

Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons

Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons

Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons

Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons

Biopolymer marker indicative of disease state having a molecular weight of 1521 daltons

Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons

Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons

Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons

Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons

Growing community of inventors

Oakville, Canada

Tammy Vrees